Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours

Polish Journal of Pathology

Volumn 58, Issue 1, 2007, Pages 23-33

  Kasprzak, Aldona ^a   Zabel, Maciej ^a   Biczysko, Wiesława ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; GENE PRODUCT; NEURON SPECIFIC ENOLASE; SYNAPTOPHYSIN;

CELL GRANULE; HUMAN; IMMUNOCYTOCHEMISTRY; LUNG TUMOR; MORPHOLOGICAL TRAIT; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PARACRINE SIGNALING; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; ULTRASTRUCTURE;

CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; NEUROENDOCRINE TUMORS; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SYNAPTOPHYSIN; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN THIOLESTERASE;

EID: 34248670173     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Abbona G, Papotti M, Viberti L, Maori L, Stella A, Bussolati G: Chromogranin A gene expression in non-small cell lung carcinomas. J Pathol 1998, 186, 151-156.
2. Addis BJ, Hamid Q, Ibrahim NB, Fahey M, Bloom SR, Polak JM: Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung. J Pathol 1987, 153, 137-150.
3. Anbazhagan R, Tihan T, Bornman DM, Johnston JC, Saltz JH, Weigering A, Piantadosi S, Gabrielson E: Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res 1999, 59, 5119-5122.
4. Ando S, Suzuki M, Yamamoto N, Iida T, Kimura H: The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 2004, 24, 1941-1946.
5. Arrigoni MG, Woolner LB, Bernatz PE: Atypical carcinoid tumours of the lung. J Thorac Cardiovasc Surg 1972, 64, 413-421.
6. Baldi A, Groger AM, Esposito V, Di Marino MP, Ferrara N, Baldi F: Neuroendocrine differentiation in non-small cell lung carcinomas. In Vivo 2000, 14, 109-114.
7. Ball DW: Achaete-scute homolog-1 and Notch in lung neuro endocrine development and cancer. Cancer Lett 2004, 204, 159-169.
8. Ball DW, Azzoli CG, Baylin SB, Chi D, Dou S, Donis-Keller H, Cumaraswamy A, Borges M. Nelkin BD: Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumours. Proc Natl Acad Sci USA 1993, 90, 5648-5662.
9. Barakat MT, Meeran K, Bloom SR: Neuroendocrine tumours. Endocrine-Related Cancer 2004, 11, 1-18.
10. Barbarescchi M, Mariscotti C, Barberis M, Frigo B, Mosca L: Large cell neuroendocrine carcinoma of the lung. Tumori 1989, 31, 583-588.
11. Barlesi F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F, Kleisbauer JP: Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004, 98, 357-362.
12. Bergh J, Arnberg H, Eriksson B, Lundqvist G: The release of chromogranin A and B like activity from human lung cancer cell lines. A potential marker for a subset of small cell lung cancer. Acta Oncol 1989, 28, 651-654.
13. Bergh J, Esscher T, Steinholtz L, Nilsson K, Pahlman S: Immunocytochemical demonstration of neuron-specific enolase (NSE) in human lung cancers. Am J Clin Pathol 1985, 84, 1-7.
14. Biczysko W, Młynarczyk W, Błotna-Filipiak M, Przybyłowski P: Neuroendocrine component of different types of the pulmonary carcinoma. Folia Morphol 1994, 53, 149-155.
15. Bittencourt Rosas SL, Caballero OL, Dong SM, da Costa Carvalho Mda G, Sidransky D, Jen J: Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 2001, 170, 73-79.
16. Borges M, Linnoilla RI, van de Velde HJ, Chen H, Nelkin BD, Mabry M, Baylin SB, Ball DW: An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature 1997, 386, 852-855.
17. Brown WH: A case of pluriglandular syndrome: diabetes of bearded woman. Lancet II 1928, 1022-1023.
18. Carles J, Rosell R, Ariza A, Pellicer I, Sanchez JJ, Fernandez-Vasalo G, Abad A, Barnadas A: Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer. Lung Cancer 1993, 10, 209-219.
19. Carnaghi C, Rimassa L, Garassimo I, Santoro A: Clinical significance of neuroendocrine phenotype in non-small celllung cancer. Ann Oncol 2001, 12 Suppl 2, S 119-123.
20. Chen H, Biel MA. Borges MW, Thiagalingam A, Nelkin BD, Baylin SB, Ball DW: Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: transcriptional regulation by dual inhibitory regions. Cell Growth Differ 1997, 8, 677-686.
21. Dardick I, Christensen H, Stratis M: Immunoelectron microscopy for chromogranin A in small cell neuroendocrine carcinoma of lung. Utrastruct Pathol 1996, 20, 361-368.
22. Deftos LJ: Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. Endocr Rev 1991, 12, 181-187.
23. Dhillon AP, Rode J, Dhillon DP, Moss E, Thompson RJ, Spiro SG, Corrin B: Neural markers in carcinoma of the lung. Br J Cancer 1985, 51, 645-652.
24. Drivsholm L, Paloheimo LI, Osterlind K: Chromogranin A, a significant prognostic factor in small cell lung cancer. Br J Cancer 1999, 81, 667-671.
25. Doran JF, Jackson P, Kynoch PAM, Thompson RJ: Isolation of PGP 9.5, a new human neuron-specific protein detected by high resolution two-dimensional electrophoresis. J Neurochem 1983, 40, 1542-1547.
26. Dunnill MS, Gatter KC: Cellular heterogeneity in lung cancer. Histopathology 1986, 10, 461-475.
27. Ermisch B, Schwechheimer K: Protein gene product (PGP) 9.5 in diagnostic (neuro-) oncology. An immunomorphological study. Clin Neuropathol 1995, 14, 130-136.
28. Ferrari L, Seregni E, Bajetta E, Martinetti A, Bombardieri E: The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours. Anticancer Res 1999, 19, 3415-3427.
29. Ferrigno D, Buccheri G, Giordano C: Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer 2003, 41, 311-320.
30. Gatter KC, Dunnill MS, Gerdes J, Stein H, Mason DY: New approach to assessing lung tumours in man. J Clin Pathol 1986, 39, 590-593.
31. Giovanella L, Ceriani L, Bandera M, Garancini S: Immunoradiometric assay of chromogranin A in the diagnosis of small cell lung cancer. Comparative evaluation with neuron-specific enolase. Int J Biol Markers 2001, 16, 50-55.
32. Gould VE, Lee I, Warren WH: Immunohistochemical evaluation of neuroendocrine cells and neoplasm of the lung. Pathol Res Pract 1988, 183, 200-213.
33. Gould VE, Wiedenmann B, Lee I, Schwechheimer K, Dockhorn-Dworniczak B, Radosevich JA, Moll R, Franke WW: Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochernistry. Am J Pathol 1987, 126, 243-257.
34. Grenier J, Pujol JL, Guilleux F, Daures JP, Pujol H, Michel FB: Cyfra 21-1, a new marker of lung cancer. Nucl Med Biol 1994, 21, 47-476.
35. Hamid Q, Corrin B, Sheppard MN, Huttner WB, Polak JM: Expression of chromogranin A mRNA in small cell carcinoma of the lung. J Pathol 1991, 163, 293-297.
36. Haskovcova I, Povysil C: Use of immunohistochemical markers in the diagnosis of bronchogenic tumors. Sb Lek 1995, 96, 105-109.
37. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J: PGP9.5 as a candidate tumor marker for non-small celllung cancer. Am J Pathol 1999, 155, 711-715.
38. Hoster M, Kirchheiner T, Ruhle KH: The neuron-specific enolase tumor marker as a prognostic indicator in small cell bronchial carcinoma. Pneumologie 1995, 49, 470-474.
39. Ishida T, Yokoyama H, Sugio K, Kaneko S, Sugimachi K, Hara N, Ohta M: Carcinoid tumor of the lung: clinicopathological and immunohistochemical studies. Eur J Surg Oncol 1992, 18, 180-187.
40. Ito T, Udaka N, Okudela K, Yazawa T, Kitamura H: Mechanisms of neuroendocrine differentiation in pulmonary neuroendocrine cells and small cell carcinoma. Endocr Pathol 2003, 14, 133-139.
41. Jackson P, Thompson RJ: The demonstration of new human brain-specific proteins by high-resolution two-dimensional polyacrylamide gel electrophoresis. J Neurol Sci 1981, 49, 429-438.
42. Jensen SM, Gazdar AF, Cuttitta F, Russell EK, Linnoila RI: A comparison of synapthophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines. Cancer Res 1990, 50, 6068-6074.
43. Jesner R: Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol 2001, 70, 179-182
44. Jiang SX, Kameya T, Asamura H, Umezawa A, Sato Y, Shinada J, Kawakubo Y, Igarashi T, Nagai K, Okayasu I: hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol 2004, 17, 222-229.
45. Johansson L, Andersson C, Albin M: Immunohistochemical study of 158 lung carcinoma. APMIS 1992, 100, 914-924.
46. Johnson BE, Cortazar P, Kelley MJ: Current perpectives in the treatment of small cell lung cancer. Lung Cancer 1997, 18, Suppl 2, 125-126.
47. Jorgensen LG, Hansen HH, Cooper EH: Neuron specific enolase, carcinoembryonic antigen and lactate dehydrogenase as indicators of disease activity in small cell lung cancer. Eur J Cancer Clin Oncol 1989, 25, 123-128.
48. Jorgensen LG, Hirsch FR, Skov BG, Osterlind K, Cooper EH, Larsson LI: Occurrence of neuron specific enolase in tumour tissue and serum in small cell lung cancer. Br J Cancer 1991, 63, 151-153.
49. Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernandez JR, Johnson PW, Lober J, Splinter TA, Szturmowicz M: Serum neuron-specific enolase (S-NSE) and the prognosis in small celllung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer 1996, 74, 463-467.
50. Kaiser E, Kazmits R, Pregant P, Burghuber O, Worofka W: Clinical biochemistry of neuron specific enolase. Clin Chim Acta 1989, 31, 13-31.
51. Kakinuma H, Mikami T, Iwabuchi K, Yokoyama M, Hattori M, Ohno E, Kuramoto H, Jiang SX, Okayasu I: Diagnostic findings of bronchial brush cytology for pulmonary large cell neuroendocrine carcinomas: comparison with poorly differentiated adenocarcinomas, squamous cell carcinomas, and small cell carcinomas. Cancer 2003, 99, 247-254.
52. Karnak D, Beder S, Kayacan O, Ibis E, Olfaz G: Neuron-specific enolase and lung cancer. Am J Clin Oncol 2005, 28, 586-590.
53. Kasai K, Kameya T, Kawakubo Y, Sato Y, Wada C, Itoh H: Pulmonary large cell carcinoma expressing neuroendocrine markers: the morphological, biological, and neuroendocrine features of their cell lines and surgical cases. Jpn J Cancer Res 1992, 83, 1002-1010.
54. Kaufmann O, Georgy T, Dietel M: Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin section. Hum Pathol 1997, 28, 1373-1378.
55. Kayser K, Schmid W, Ebert W, Wiedenmann B: Expression of neuroendocrine markers (neuronspecific enolase, synaptophysin and bombesin) in carcinoma of the lung. Pathol Res Pract 1988, 183, 412-417.
56. Kobayashi S, Okada S, Hasumi T, Sato N, Fujimura S: The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer. Tohoku J Exp Med 1999, 189, 37-49.
57. Langley K: The neuroendocrine concept today. Ann of NY Acad Sci 1994, 733, 1-17.
58. Lee I, Gould VE, Moll R, Wiedenmann B, Franke WW: Synaptophysin expressed in the bronchopulmonary tract: neuroendocrine cells, neuroepithelial bodies, and neuroendocrine neoplasms. Differentiation 1987, 34, 115-125.
59. Lin WM, Hsieh ST, Huang IT, Griffin JW, Chen WP: Ultrastructural localizaion and regulation of protein gene product 9.5. Neuroreport 1997, 8, 2999-3004.
60. Molina R, Filella X, Auge JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Vinolas N, Marquez A, Barreiro E, Borras J, Viladiu P: Tumor markers (CEA, CA 125, CYFRA21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol 2003, 24, 209-218.
61. Moss F, Bobrow LG, Sheppard MN: Expression of epithelial and neural antigens in small cell and non small cell lung carcinoma. J Pathol 1986, 149, 103-111.
62. Nitta T, Fukuoka M, Masuda N, Kusunoki Y, Matsui K, Kudoh S, Hiroshima T, Yana T, Ito K, Takada M: Significance of serum neuron-specific enolase as a predictor of relapse of small cell lung cancer. Jpn J Clin Oncol 1995, 25, 179-183.
63. Nobels FRE, Kwekkeboom DJ, Coopmans W, Schoenmakers CHH, Lindemans J, De Herder WW, Krenning EP, Bouillon R, Lamberts SWJ: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82, 2622-2628.
64. Nutini S, Capelli G, Benucci A, Catalani C, Nozzoli F: Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer. Int J Biol Markers 1990, 5, 198-202.
65. Piehl MR, Gould VE, Warren WH. Lee I, Radosevich JA, Ma YX, Rosen ST: Immunohistochemical identification of exocrine and neuroendocrine subsets of large cell lung carcinomas. Pathol Res Pract 1988, 183, 675-682.
66. Polak JM, Bloom SR: Immunocytochemistry of the diffuse neuroendocrine system. In: Immunocytochcmistry. Polak JM and van Noorden S (eds) Wright, Bristol, 1986, 328-348.
67. Poola I, Graziano SL: Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines. J Exp Clin Cancer Res 1998, 17, 165-173.
68. Portela-Gomes GM, Grimelius L, Johansson H, Wilander E, Stridsberg M: Chromogranin A in human neuroendocrine tumors: an immunocytochemical study with region-specific antibodies. Am J Surg Pathol 2001, 25, 1261-1267.
69. Portela-Gomes GM, Grimelius L, StridsbergM, Bresaola E, Viale G, Pelosi G: Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. Virchows Arch 2005, 446, 604-612.
70. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003, 39, 131-138.
71. Rehm H, Wiedenmann B, Betz H: Molecular characterization of synaptophysin, a major calcium-binding protein of the synaptic vesicle membrane. The EMBO J 1986, 5, 535-541.
72. Rode J, Dhillon AP, Doran JF, Jackson P, Thompson RJ: PGP9.5, a new marker for human neuroendocrine tumours. Histopathology 1985, 9, 147-158.
73. Ruibal A, Nunez MI, Rodriguez J, Jimenez L, Del Rio MC, Zapatero J: Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung. Int J Biol Markers 2003, 18, 188-194.
74. Said JW, Vimadalal S, Nash G, Shintaku IP, Heusser RC, Sassoon AF, Lloyd RV: Immunoreactive neuron-specific enolase, bombesin, and chromogranin as markers for neuroendocrine lung tumors. Hum Pathol 1985, 16, 236-240.
75. Sasaki H, Yukiue H, Moriyama S, Kobayashi Y, Nakashima Y, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y: Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn J Clin Oncol 2001, 31, 532-535.
76. Satoh H, Ishikawa H, Kurishima K, Yamashita YT, Ohtsuka M, Sekizawa K: Cut-off level of NSE to differentiate SCLC from NSCLC. Oncol Rep 2002, 9, 581-583.
77. Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E: Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer. Anticancer Res 2000, 20, 5053-5058.
78. Sheppard MN: Specific markers for pulmonary tumours. Histopathology 2000, 36, 273-276.
79. Sheppard MN, Corrin B, Bennett MH. Marangos PJ, Bloom SR, Polak JM: Immunocytochemical localization of neuron specific enolase in small cell carcinomas and carcinoid tumours of the lung. Histopathology 1984, 8, 171-181.
80. Shibayama T, Veoka H, Nishii K, Kiura K, Tabata M, Miyatake K, Kitajima T, Harada M: Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small celllung cancer (SCLC). Lung Cancer 2001, 32, 61-69.
81. Shy SW, Lee WH, Chou MC, Lai YS, Tu YC: Small cell lung carcinoma: clinicopathological, immunohistochemical, and ultrastructural study. J Surg Oncol 1990, 45, 146-161.
82. Silver MM, Lines LD, Hearn SS: Immunogold detection of chromogranin A in the neuroendocrine tumor. Ultrstruct Pathol 1993, 17, 83-92.
83. Sloman A, D'Amico F, Yousem SA: Immunohistochemical markers of prolonged survival in small cell carcinoma of the lung. An immunohictochemical study. Arch Pathol Lab Med 1996, 120, 465-472.
84. Sobol RE, O'Connor DT, Addison J, Suchocki K, Royston I, Deftos LJ: Elevated serum chromogranin A concentrations in small celllung carcinoma. Ann Intern Med 1986, 105, 698-700.
85. Soga J, Yakuwa Y: Bronchopulmonary carcinoids: an analysis of 1875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties. Ann Thorac Cardiovasc Surg 1999, 5, 211-219.
86. Springall DR, Lackie P, Levene MM, Marangos PJ, Polak JM: Immunostaining of neuron-specific enolase is a valuable aid to the cytological diagnosis of neuroendocrine tumours of the lung. J Pathol 1984, 143, 259-265.
87. Stahlman MT, Kasselberg AG, Orth DN, Gray ME: Ontogeny of neuroendocrine cells in human fetal lung. II. An immunohistochemical study. Lab Invest 1985, 52, 52-60.
88. Sumiyoshi Y, Shirakusa T, Yamashita Y, Maekawa T, Hideshima T, Sakai T, Kawahara K, Kikuchi M: Detection of chromogranin A mRNA in small cell lung carcinoma using a new, highly sensitive in situ hybridization method with non-radioisotope oligonucleotide probe. Cancer 1998, 82, 468-473.
89. Sunday ME, Haley KJ, Sikorski K, Graham SA, Emanuel RL, Zhang F, Mu QQ, Shahsafaei A, Hatzis D: Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasm. Oncogene 1999, 18, 4336-4347.
90. Szturmowicz M: Markery nowotworowe w raku płuca. Medycyna po Dyplomie 2005, 14, 190-198.
91. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A: PGP 9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology 2003, 50, 1278-1280.
92. Tezel E, Hibi K, Nagasaki T, Nakao A: PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000, 6, 4764-4767.
93. Taneja TK, Sharma SK: Markers of small cell lung cancer. World J Surg Oncol 2004, 2, 10, doi: 10.1186/1477-7819-2-10
94. Thompson RJ, Doran JF, Jackson P, Chilton AP, Rode J: PGP 9.5 - a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983, 278, 224-228.
95. Travis WD: The concept of pulmonary neuroendocrine tumours. In: Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARCPress, Lyon 2004.
96. rd ed. Springer-Verlag: Berlin, 1999.
97. Travis WD, Gal AA, Colby TV, Klimstra DS., Folk R, Koss MN: Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998, 29, 272-279.
98. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, Koss MN: Survival analysis of 200 pulmonary neuroendocrine tumours with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998, 22, 934-944.
99. Varndell IM, Lloyd RV, Wilson BS, Polak JM: Ultrastructural evidence of chromogranin: a potential marker for the electron microscopic recognition of endocrine secretory granules. Histochem J 1985, 17, 981-992.
100. Vyberg M, Horn T, Francis D, Askaa J: Immunohistochemical identification of neuron-specific enolase, synaptophysin, chromogranin and endocrine granule constituent in neuroendocrine tumours. Acta Histochem Suppl 1990, 38, 179-181
101. Weynants P, Humblet Y, Canon JI, Symann M: Biology of small cell lung cancer: and overview. Eur Respir J 1990, 3, 699-714.
102. Wiedenmann B: Synaptophysin. A widespread constituent of small neuroendocrine cells and a new tool in tumor diagnosis. Acta Oncol 1991, 30, 435-444.
103. Wiedenmann B, Franke WW: Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr. 38,000 characteristic of presynaptic vesicles. Cell 1985, 41, 1017-1028.
104. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE: Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986, 83, 3500-3504.
105. Wiedenmann B, Hutter WB: Synaptophysin and chromogranin/ secretogranins - widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis. Virchows Arch B Cell Pathol Incl Mol Pathol 1989, 58, 95-121.
106. Wilkins EW, Grillo HC, Moncure AC, Scannell JG: Changing times in surgical management of bronchopulmonary carcinoid tumor. Ann Thorac Surg 1984, 38, 339-344.
107. Wilkinson KD, Lee K, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J: The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989, 246, 670-673.
108. Wilson TS, McDowell EM, Marangos PJ, Trump BF: Histochemical studies of dense-core granulated tumors of the lung. Neuron-specific enolase as a marker for granulated cells. Arch Pathol Lab Med 1985, 109, 613-620.
109. Winkler H, Fisher-Colbrie R: The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992, 49, 497-528.
110. Yanagisawa K, Xu BJ, Carbone DP, Caprioli RM: Molecular fingeprinting in human lung cancer. Clin Lung Cancer 2003, 5, 113-118.
111. Yesner R: Heterogeneity of so-called neuroendocrine lung tumors. Exp Mol Pathol 2001, 70, 179-182.
112. Younossian AB, Brundler M-A, Totsch M: Feasibility of the new WHO classification of pulmonary neuroendocrine tumours. Swiss Med Wkly 2002, 132, 535-540.
113. Zabel M: Immunocytochemiczne markery nowotworów neuroendokrynowych. In: Immunocytochemia. Zabel M, ed, PWN, 1999, Chapter 17, 355-373.